Plain-English translation of NCT04695106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether dabigatran combined with —two blood-clotting medications—can protect your heart as well as the standard three-medication approach while causing fewer bleeding problems. You qualify if you have an irregular heartbeat called atrial fibrillation and recently had a heart stent placed to open a blocked artery. The study will randomly assign you to one of two treatment groups and follow you for one year.
Patients with both an irregular heartbeat and a recent heart stent face a difficult choice: they need blood thinners to prevent stroke from the irregular heartbeat, but also need other medications to prevent the stent from clotting. The current standard treatment uses three medications, which causes major bleeding in about 1 out of 4 patients per year. Doctors are looking for a safer two-medication combination that still protects your heart.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either two or three blood-clotting medications for up to 12 months. If assigned to the two-medication group, you will take dabigatran (an anticoagulant) and (an antiplatelet medication); if assigned to the standard group, you will take dabigatran, , and . You will have follow-up visits to check how well the treatment is working, monitor for any bleeding or heart problems, and discuss any side effects. The study will track your health outcomes over one year to compare the safety and effectiveness of both approaches.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Poland